What does HLAB 5701 refer to in the context of NRTI use?

HLAB 5701 refers to a specific genetic test that determines an individual's risk of developing hypersensitivity reactions to the antiretroviral drug Abacavir, which is a nucleoside reverse transcriptase inhibitor (NRTI). Identifying the presence of this particular allele in a patient's genetic makeup is crucial before prescribing Abacavir, as those who test positive for HLAB 5701 are at a significantly higher risk for severe and potentially life-threatening hypersensitivity reactions.

By ensuring that patients undergo this genetic testing prior to the initiation of Abacavir treatment, healthcare providers can improve patient safety and avoid adverse drug reactions. This preemptive testing is part of personalized medicine, allowing for better-targeted therapies tailored to an individual’s genetic profile.